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determining MIDs for the SF-36 domain and summary scores
was investigated for the ﬁrst time in patients with active CD. This
enables a more meaningful interpretation of SF-36 scores in CD
patients.
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PROTON PUMP INHIBITORS FORTHE INITIALTREATMENT
OF GASTROESOPHAGEAL REFLUX DISEASE (GORD)
SYMPTOMS IN PATIENTS WITH REFLUX OESOPHAGITIS:
A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED
TRIALS
Edwards SJ, Borrill J
AstraZeneca UK Ltd, Luton, UK
OBJECTIVES: To compare the efﬁcacy of esomeprazole with
that of the European licensed standard doses of PPIs for the relief
of GORD-associated symptoms in patients with reﬂux oesoph-
agitis (i.e. esomeprazole 40 mg once-daily compared with lanso-
prazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, or
rabeprazole 20 mg once-daily). METHODS: A systematic review
of CENTRAL, BIOSIS, EMBASE and MEDLINE for randomised
controlled trials (RCTs) in patients with erosive oesophagitis was
conducted in January 2007. Data on relief of GORD symptoms
at 4 weeks were extracted and re-analysed if not analysed by
intention-to-treat. The summary effect estimate (relative risk
[RR]) was calculated by meta-analysis using a ﬁxed-effects
model. Publication bias was assessed using funnel plots.
RESULTS: Of 347 papers identiﬁed in the literature search, 11
were found to be head-to-head comparisons of a standard dose
of PPI and esomeprazole 40 mg. Five RCTs were excluded as
they did not contain any extractable data on the required out-
comes at 4 weeks. The remaining 6 RCTs were all randomised,
double-blind, double-dummy, had appropriate patient follow-up,
and were of sufﬁcient quality to be included. A meta-analysis
of complete resolution of heartburn showed that signiﬁcantly
more patients were heartburn-free with esomeprazole versus
other standard-dose PPIs (RR 1.08; 95% CI: 1.06 to 1.11;
p < 0.00001). Heartburn resolution was consistent across all
degrees of initial severity (mild, moderate, severe). There were no
signiﬁcant differences in treatment effect for dysphagia and epi-
gastric pain, but signiﬁcantly fewer patients had acid regurgita-
tion with esomeprazole versus other standard-dose PPIs (RR
1.03; 95% CI: 1.01 to 1.05; p = 0.002). Publication bias did not
appear to affect the results signiﬁcantly. CONCLUSION: Esome-
prazole signiﬁcantly improves symptoms of heartburn and acid
regurgitation when compared with other standard-dose PPIs in
patients with reﬂux oesophagitis.
GI DISORDERS—Cost Studies
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BUDGET IMPACT OF A UNIVERSAL ROTAVIRUS
VACCINATION PROGRAMME WITH ROTATEQ® IN FRANCE
Trichard M, Largeron N, Soum S, Saint-Sardos C
sanoﬁ pasteur MSD, Lyon, France
OBJECTIVES: The objective of the study was to assess the
budget impact of a universal rotavirus vaccination programme
with RotaTeq® in France from the French social security (SS)
and societal perspectives. METHODS: A decision analytic model
was developed following a birth cohort up to age 5. Epidemio-
logical parameters were taken from the French REVEAL study (a
prospective epidemiological study conducted in 2004–2005) and
from the literature. Costs were assessed by combining health care
resource utilization collected in the REVEAL study and unit
costs from ofﬁcial sources. Intention-to-treat effectiveness of the
vaccine was taken from a large worldwide clinical trial (REST
study, 70,000 children). The model estimates RVGE, vaccination
costs and net costs of a rotavirus vaccination programme with
RotaTeq® (90% coverage rate and current vaccine price) from
the French SS and societal perspectives. RESULTS: From the
French SS perspective, the introduction of RotaTeq® would
reduce the RVGE costs by 74% for a birth cohort followed up to
age 5, from €62.9 million to €16.2 million. The vaccination costs
would be €71.5 million. As 92% of RVGE costs occur during the
ﬁrst 24 months of life, 60% of the vaccination costs would be
recovered through prevented health care costs 2 years after the
implementation of the rotavirus vaccination programme. From
the societal perspective, the introduction of RotaTeq® would
reduce the RVGE costs by 75%, from €117.2 million to €29.6
million. The vaccination costs would be €110.1 million. As
89% of RVGE costs occur during the ﬁrst 24 months of life, 70%
of the vaccination costs would be recovered 2 years after
the implementation of the rotavirus vaccination programme.
CONCLUSION: In France, 60% and 70% of the rotavirus vac-
cination programme costs with RotaTeq® would be recovered 2
years after its implementation by the French SS and society
respectively.
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OBJECTIVES: This study evaluated cost, percentage of success-
fully treated patients and cost per successfully treated patient
comparing two branded Proton Pump Inhibitors (PPIs) often
prescribed in the UK, lansoprazole (oro-dispersible tablets) and
esomeprazole (tablets), for the acute management of uninvesti-
gated dyspepsia. METHODS: A decision analytic model was
used to simulate expected costs and outcomes in patients with
uninvestigated dyspepsia indicated for treatment with a PPI. The
primary outcome measure was the percentage of patients cured
within eight weeks, derived from studies directly comparing the
efﬁcacy of the two agents in this patient population. The analysis
considered use of PPI drugs, general practitioner visits, subse-
quent specialist consultations and endoscopy. Costs were esti-
mated from the perspective of the UK National Health Service.
Stochastic methods were used to determine conﬁdence intervals.
RESULTS: The expected proportion of patients healed after 8
weeks was 88.9% (95% CI 87.7%–90.1%) with lansoprazole
and 92.4% (91.4–93.3%) with esomeprazole. The expected cost
of treatment per patient with lansoprazole was £94.05 (£85.17–
£104.58) compared with £118.94 (£110.28–£128.83) with
esomeprazole. The incremental cost-effectiveness of esome-
prazole compared to lansoprazole was £711.77 (£465.41–
£1344.52) per additional patient achieving healing at eight
weeks. Sensitivity analysis exploring cost-effectiveness over 12
weeks found a cost-effectiveness of £2213 (£1487–£4087) per
additional patient achieving healing. Esomeprazole was signiﬁ-
cantly more expensive than lansoprazole (26% more at 8 weeks;
37% more at 12 weeks; p < 0.05 in both comparisons) and
delivered a small but diminishing therapeutic advantage (3.9% at
8 weeks; 1.9% at 12 weeks). CONCLUSION: For patients pre-
senting with uncomplicated reﬂux symptoms, treatment with
esomeprazole was signiﬁcantly more expensive than lansoprazole
and its therapeutic advantage was small.
A352 Abstracts
